Clinical trial recruitment is an operations problem as much as it is a data problem. A model can point to potential participants but it cannot complete consent, arrange visits, or close gaps in reach. The immediate question for sponsors, contract research organizations (CROs), and site…
Clinical trial recruitment is commonly treated as an outreach problem: run ads, call lists, train sites, and hope the eligible people respond. What actually determines who enrolls is shaped long before outreach begins by where the trial sits, who the protocol screens in or out,…
Clinical trial recruitment is often treated like a counting exercise: if a country or region has enough patients, enrollment will follow. The honest operational problem is different. A site can have a pool of patients and still be unable to find, screen, and convert them…
Digitizing traditional medicine knowledge for research or model training creates a workflow problem most institutions notice too late: the dataset moves through teams, vendors, and repositories, and somewhere along the way the record of who consented to what gets detached. By the time an AI…
Completing target enrollment is cause for celebration, but the hard work of keeping participants engaged begins the moment the last consent is signed. Clinical trial participant engagement is a per-person problem: every enrollee has a different day-0, their own visit cadence, and their own language…
Clinical trial recruitment increasingly includes unconventional channels. Influencer videos and short-form social posts can produce a surge of inquiries. The bottleneck shows up once the first wave arrives: getting eyeballs is only step one. The operational handoffs determine whether those eyeballs become enrolled participants and…
Decentralized clinical trials change the work from site-centric to per-participant. That shift is operationally simple to describe but much harder to run: each participant has their own enrollment date, reminder cadence, and escalation path. As the decentralized clinical trial platform market expands rapidly (recent trade…
Clinical trial recruitment is often thought of as a marketing problem, but at its core it is an operational one. Each potential participant has a different history, different constraints, and a personal timeline; solving recruitment in rare-disease studies means designing communications and intake workflows that
Clinical trial retention and late-stage data integrity are operational problems, not marketing problems. When a Phase 3 study crosses the enrollment finish line, the work shifts from finding participants to keeping them engaged and collecting high-quality patient-reported outcomes (PRO).
Clinical trial recruitment is as much an operational problem as it is a scientific one. Trials can be derailed not by the protocol but by timing: an outbreak near a site, expiring supplies, or a sudden change in local vaccine policy can all compress the
Putting AI in clinical trials is not just a technology shift. It is an operational one. Embedding AI promises faster patient recruitment, smarter site selection, and earlier detection of data issues. What operations leaders need to worry about is how those AI-driven recommendations change day-to-day
Clinical trial workflows are fundamentally a per-person scheduling problem. Each participant has their own baseline visit, dosing day, and follow-up window, and those individual timelines drive when you must collect patient-reported outcome (PRO) data, run blinded biomarker checks, and perform safety follow-ups. When an interim